CAG
VRDN icon

Crestwood Advisors Group’s Viridian Therapeutics VRDN Stock Holding History

Crestwood Advisors Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-800
Closed -$25K – 260
2019
Q2 		$25K Buy
+800
New +$32.1K ﹤0.01% 240

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crestwood Advisors Group's VRDN Position: Q3 2019 in Review

Crestwood Advisors Group sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 800 shares — an estimated $25K sold.

Crestwood Advisors Group first reported a position in VRDN in Q2 2019 and held it in 1 quarter. The position peaked at $25K in Q2 2019. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

  • Crestwood Advisors Group reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Crestwood Advisors Group sold 800 Viridian Therapeutics shares in Q3 2019, an estimated $25K.
  • Crestwood Advisors Group first reported a position in Viridian Therapeutics in Q2 2019 and held it in 1 quarter.
  • Crestwood Advisors Group's Viridian Therapeutics position peaked at $25K in Q2 2019.
  • 33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Crestwood Advisors Group's 13F filing for Q3 2019, filed 13 Nov 2019.